GANX

GANX

USD

Gain Therapeutics Inc. Common Stock

$1.660-0.150 (-8.287%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$1.810

最高价

$1.810

最低价

$1.660

成交量

0.57M

公司基本面

市值

59.7M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.68M

交易所

NGM

货币

USD

52周价格范围

最低价 $1.41当前价 $1.660最高价 $2.81

相关新闻

Analyst Upgrades

BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Gain Therapeutics with a Buy and maintains $9 price target.

查看更多
BTIG Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics with a Buy and maintains $8 price target.

查看更多
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
GlobeNewswire

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of

查看更多
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Analyst Upgrades

Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains Gain Therapeutics with a Buy and raises the price target from $5 to $7.

查看更多
Maxim Group Maintains Buy on Gain Therapeutics, Raises Price Target to $7
GlobeNewswire

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants Plasma exposures in patients within projected therapeutic range and comparable to

查看更多
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®